SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data presented at the World Muscle Society meeting, including slower upper-limb decline after placebo patients switched to deramiocel, is driving attention. Traders largely view the findings as supportive ahead of the FDAs November review, while others question whether the open-label results resolve the agencys concerns about the trials statistical analysis.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal fourth-quarter earnings and forward guidance are the dominant focus, with traders looking for evidence that AI-driven HBM demand and tight DRAM and NAND supply can sustain strong pricing. Bullish expectations for a beat and stronger outlook compete with concerns that high expectations are already priced in, the memory cycle may prove temporary, and Netlists HBM patent action could pose a risk.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being linked to discussion of its Oracle collaboration and reported work with The Clearing House on tokenized-bank infrastructure, alongside traders belief that QNTs limited supply could amplify demand. Optimism over institutional adoption and a possible supply squeeze is tempered by concerns that the partnerships may not create direct token demand, as well as profit-taking and debate over the rallys sustainability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention amid speculation about upcoming ANKTIVA catalysts, particularly a potential FDA decision on expanding its bladder-cancer use, along with trial updates and international commercialization. Bulls expect these developments to support the companys growth and possibly pressure short sellers, while skeptics say the stock needs concrete news and sustained sales progress to break out of its volatile trading pattern.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA judges pause in the broader cannabis rescheduling case, while considering whether to add a government report on agency procedures, has delayed a recommendation investors viewed as a catalyst for the MSOS holdings. Traders debate whether the stay is a limited procedural delay or a sign of a longer wait for Schedule III; it does not undo the earlier medical-marijuana rule.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rebound and perceived technical breakout are driving attention, with bullish traders pointing to its capped token supply, anticipated V4 development, and improving DeFi/altcoin sentiment. Others remain skeptical, citing COMPs past underperformance and questioning whether those themes will translate into lasting demand.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes prolonged selloff is fueling debate over the equity raise, IZAR-1 results that some investors viewed as short of proving clear superiority in PsA, and distrust of managements communication and solo-commercialization plans. Traders are watching the planned HS BLA submission as a key regulatory catalyst, while bullish investors point to the HS data and bearish investors question the drugs differentiation and execution risks.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on positive Phase 2 results for AbCelleras ABCL635 menopause-treatment candidate and anticipation of a fuller data presentation; JPMorgans new Overweight coverage has added to the catalyst discussion. Many traders are bullish on the pipeline and recent momentum, while others flag biotech trial risk, possible pullbacks, and funding needs; speculation about a deal or short squeeze remains unconfirmed.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff has traders focused on growing competition from Kalshi and Polymarket, with concerns that prediction markets could take wagering share and that DraftKings investment in its own offering will pressure margins. Bears see competitive and regulatory uncertainty as a threat, while bulls point to rising DKeX activity and argue that court rulings against competitors could benefit DraftKings.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised 2026 revenue outlook, reflecting stronger demand for its cancer treatments, is driving the surge, with analysts also lifting their views. The community is broadly bullish and discussing possible short covering, while some traders caution that the sharp run-up could invite profit-taking or dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$FUNN 78.2% gross margin is probably the number that jumped out at me the most &gt;&gt; Tempe, Tucson and Chicago are the main focus now, and those U.S. locations did $4.64M in FY2026 revenue

Less clutter, cleaner numbers and now we get to see what management can do with the core business without the bs!! LFgoooo FINALLY!!!

chuck

Mr. Worldwide

Bigirish

beachlifeguy

Ray Dog

Eugene Case

StockTwits for iOS

Amfil Technologies Inc

 78.2% gross margin is probably the number that jumped out at me the most >> Tempe, Tucson and Chicago are the main focus now, and those U.S. locations did $4.64M in FY2026 revenue

Less clutter, cleaner numbers and now we get to see what management can do with the core business without the bs!! LFgoooo FINALLY!!!